Business
IMM initiatesIND-Enabling Program for Kapiglucagon
ImmuPharma PLC has initiated IND-enabling activities for its Kapiglucagon diabetes program, a proprietary glucagon prodrug for Type 1 diabetes, by engaging tranScrip Limited to develop the regulatory strategy and prepare for a pre-IND meeting with the FDA. The company plans to utilize a 505(b)(2) regulatory pathway in the United States, leveraging existing data on native glucagon, with the goal of improving solubility and formulation stability for next-generation artificial pancreas systems. This program is supported by recently approved funding intended to advance the asset over the next two years, with a projected global insulin pump market reaching $13.6 billion in sales by 2035. Disclaimer*
About this update from Immupharma Plc
This announcement contains inside information for the purposes of the UK Market Abuse Regulations ('UK MAR'). Upon publication of this announcement, this inside information (as defined in UK MAR) is now considered to be in the public domain. The person responsible for arranging the release of this announcement on behalf of the Company is tim mccarthy, Chief Executive Officer. 5 May 2026 ImmuPharma PLC ("ImmuPharma" or the "Company") ImmuPharma Initiates IND-Enabling Program for Kapiglucagon to treat Diabetes ImmuPharma plc, (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce the initiation of IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited ("tranScrip"). Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. About Kapiglucagon Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. Through this innovation, ImmuPharma aims to contribute to next-generation diabetes care, in which artificial pancreas systems, may reduce disease burden while improving metabolic control and patient quality of life. The global Insulin Pump market is forecast to reach $13.6bn sales by 2035 (Source: Roots Analysis). ImmuPharma believes Kapiglucagon represents an important strategic opportunity, alongside its lead asset, P140. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway...